U.S. Food and Drug Administration approved VKT Pharma’s reformulated Ranitidine tablets in 150 mg and 300 mg strengths, marking the return of this important acid-reducing medication to the U.S. market after a five-year absence. The approval follows extensive safety testing and manufacturing improvements that address previous concerns about N-nitrosodimethylamine (NDMA) impurity formation during the product’s shelf-life.
https://r.search.yahoo.com/_ylt=AwrFGXZPwCVpQx0DOMvrFAx.;_ylu=Y29sbwNiZjEEcG9zAzEEdnRpZAMEc2VjA3Ny/RV=2/RE=1765291343/RO=10/RU=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2fpsg%2fPSG_020251.pdf/RK=2/RS=Plhnhs5aWfwgBW5vlMrw3fb3yyc-